Retro Biosciences, backed by Sam Altman, is raising $1 billion to extend human lifespan
SMRTR summary
Retro Biosciences, a San Francisco biotech startup aiming to extend human lifespans, is raising a $1 billion Series A round with OpenAI CEO Sam Altman participating. Altman previously provided the company's $180 million seed funding. The startup plans to launch trials for drugs targeting diseases like Alzheimer's and recently trained an AI model with OpenAI to convert cells into stem cells. Retro Biosciences joins other billionaire-backed longevity efforts, including Altos Labs and Unity Biotechnology.
SMRTR provides this summary for quick context. The original article belongs to Daily.dev.
Read the original article